| NCT ID | NCT01619553 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UConn Health |
| Condition | Keloid |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,000 participants |
| Start Date | 2009-04 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,000 participants in total. It began in 2009-04 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Keloids have a strong genetic component. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for keloids or contribute to keloid scarring.
Eligibility Criteria
Inclusion Criteria: * keloids; * unaffected individuals only if part of a participating keloid family Exclusion Criteria: * no keloids; * unaffected individuals only as part of a participating keloid family
Contact & Investigator
Ernst Reichenberger, PhD
PRINCIPAL INVESTIGATOR
UConn Health
Frequently Asked Questions
Who can join the NCT01619553 clinical trial?
This trial is open to participants of all sexes, studying Keloid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01619553 currently recruiting?
Yes, NCT01619553 is actively recruiting participants. Contact the research team at reichenberger@uchc.edu for enrollment information.
Where is the NCT01619553 trial being conducted?
This trial is being conducted at Farmington, United States.
Who is sponsoring the NCT01619553 clinical trial?
NCT01619553 is sponsored by UConn Health. The principal investigator is Ernst Reichenberger, PhD at UConn Health. The trial plans to enroll 7,000 participants.